Q-omics provides the consensus-scored C2orf68 profile across patient tissues and cancer cell-line models. C2orf68 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C2orf68 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, C2orf68 RNA expression shows 23,082 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where C2orf68 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2orf68 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2orf68 survival associations across molecular data types. C2orf68 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2orf68 RNA expression–survival associations across cancer types. High C2orf68 expression shows unfavorable associations in ACC, UCEC, LIHC and COAD, but favorable associations in UCS and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C2orf68 RNA expression.
This table summarizes C2orf68 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for C2orf68. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2orf68 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, LIHC, LUAD and KIRC. The BLCA box plot shows higher C2orf68 RNA expression in tumor versus normal tissue (log2 FC = +1.334, t-test p < 0.001).
This table shows molecular features associated with C2orf68 in patient tissues and cancer cell lines. In patient samples, C2orf68 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C2orf68 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
